Even some classic molecular targeted drugs, such as IGF1R (insulin-like growth factor 1 receptor) inhibitors [4], VEGF (vascular endothelial growth factor) inhibitors [5] and EGFR (epidermal growth factor receptor) inhibitors [6], have been proven to fail to effectively prolong the OS time of ACC patients. This evidence concerns the gene EGFR and adrenal cortex carcinoma.